Cutting-edge practice in glaucoma care: what, how and why?
1 April 2016
| Nick Strouthidis, Winifred Nolan, Keith Barton
|
EYE - Glaucoma
More effective treatments and drug delivery modalities, implantable minimally invasive glaucoma surgical (MIGS) devices, as well as accelerating clinical research programmes, will transform the surgical and clinical management of glaucoma in the near future. There is also an ever-greater emphasis...
Neuro-ophthalmic disease patterns in Southeast Asia with particular reference to giant cell arteritis
1 April 2016
| James F (Barry) Cullen, Lakana Kumar Thavaratnam
|
EYE - Neuro-ophthalmology
As indicated in an earlier article in Eye News [1] Dr Cullen was invited in 2000 to the Singapore National Eye Centre (SNEC) as visiting Professor with a specific remit to set up a specialist neuro-ophthalmology service, which was the...
Resurfacing the ocular surface
1 April 2016
| Harminder Dua (Prof)
|
EYE - Cornea
The ocular surface (OS) is an anatomical and functional unit made of the tear film, the conjunctival, limbal and corneal epithelium, the lacrimal, mucous and meibomian glands and the lids and blink reflex. The tear film is composed of a...
It’s not all about ARED - Time for a pragmatic approach to nutrition for eye health?
1 April 2016
| Christine Purslow (Prof)
|
EYE - Cornea
Advances in treatment for retinal diseases involving neovascularisation have undoubtedly changed the future of eye care across the UK for the better, but also created great challenges for service delivery in ophthalmology, particularly within the NHS. Some statistics are starting...
Identifying drugs associated with intraoperative floppy iris syndrome
Before David Chang MD from the University of California found out about intraoperative floppy iris syndrome (IFIS), ophthalmologists were mystified each time they came across cataract surgeries that were characterised by sudden intraoperative iris prolapse and pupil constriction. The biggest...
Regulatory drug evaluations and expedited review initiatives: EU and US perspectives
1 April 2016
| Rod McNeil
|
EYE - General
The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...
